Evidence map›Paper›PMID 42911505›Full record

ReviewNeurology and therapy2026

Clobazam Use in Epilepsy: An Old Story with a New Twist. A Narrative Review.

Simone Gasparini, Renzo Guerrini

Abstract readReview
PubMed Publisher
In one paragraph

Review in Neurology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Simone GaspariniNeuroscience and Human Genetics Department, Children's Hospital AOU Meyer IRCCS, Ospedale Meyer, viale Pieraccini 24, 50139, Florence, Italy.ORCID http://orcid.org/0009-0006-3967-1065
Renzo GuerriniNeuroscience and Human Genetics Department, Children's Hospital AOU Meyer IRCCS, Ospedale Meyer, viale Pieraccini 24, 50139, Florence, Italy. renzo.guerrini@meyer.it.ORCID http://orcid.org/0000-0002-7272-7079

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clobazam (CLB), a 1,5-benzodiazepine, widely used and now available in an oral liquid formulation with a registered indication as adjunctive antiseizure medication for drug-resistant epilepsy, is characterized by a distinctive pharmacological profile. It is rapidly absorbed and extensively metabolised via CYP3A4 and CYP2C19 to its active metabolite, N-desmethylclobazam, with marked interindividual variability driven by pharmacokinetic interactions, genetic polymorphisms, and patient-specific factors. Its antiseizure effects are mediated through modulation of γ-aminobutyric acid

Indexed as

ClobazamDravet syndromeDrug-resistant epilepsyEpilepsyLennox–Gastaut syndromeOral formulation

Identifiers

PMID42911505

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.